Clinical Trials Logo

HER-2 Protein Overexpression clinical trials

View clinical trials related to HER-2 Protein Overexpression.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06187506 Not yet recruiting - Clinical trials for Non-muscle Invasive Bladder Cancer

Disitamab Vedotin Combined With BCG Therapy in HER2-expressing High-risk Non-muscle Invasive Bladder Cancer

Start date: January 2024
Phase: Phase 2
Study type: Interventional

This is a prospective, open, single-center clinical study of the anti-HER2(Human epidermal growth factor receptor-2) ADC(antibody-drug conjugate) drug Disitamab Vedotin in combination with BCG(bacillus Calmette-Guerin) therapy in very high-risk NMIBC(Non-muscle invasive bladder cancer) patients with HER2 expression (IHC 1+/2+/3+), which is being conducted in accordance with the Good Clinical Practice for Pharmaceutical Trials (GCP). Approximately 20 subjects will be enrolled in this study to evaluate the efficacy and safety of Disitamab Vedotin (2.0 mg/kg, administered intravenously every three weeks) in combination with BCG therapy.

NCT ID: NCT06055153 Not yet recruiting - Clinical trials for HER-2 Protein Overexpression

DV Combined With PD-1 and Platinum-based First-line Treatment in Patients With HER2 IHC2+/3+ ESCC

Start date: September 30, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This is a single-arm, exploratory clinical study.

NCT ID: NCT04215159 Not yet recruiting - Clinical trials for HER-2 Protein Overexpression

Trastuzumab Biosimilar (Samfenet®) Plus Treatment of Physician's Choice (TPC) in Patients With HER2-positive Solid Tumor

BIOs-Her
Start date: December 30, 2019
Phase: Phase 2
Study type: Interventional

HER2 signaling pathway abnormalities or HER2 overexpression can be seen in various types of solid tumors apart from breast cancer or hepatic cancer. In this regardHER2 targeting therapy has been proven to be effective in colorectal cancer, gallbladder cancer, and salivary gland tumors. Although HER2 targeted-treatment Trastuzumab biosimilar is clinically being used after gaining official permission recently, clinical data for this use is still lacking, especially regarding experiences of combination with various cytotoxic chemotherapy agents. Notably, techniques to separate and extract a small sized ciculating tumor DNA (ctDNA) in patient's blood originated from a tumor is being developed and improved along with introduction of Next-generation sequencing (NGS) technique enabling a comprehensive genetic testing. The aim of this study is to evaluate the efficacy and safety of Trastuzumab biosimiler and to investigate the association between ctDNA and clinical outcomes such as disease response, progression-free survival, and overall survival.

NCT ID: NCT04179656 Not yet recruiting - Solid Tumor Clinical Trials

The Basket Study of Pyrotinib Maleate for HER2-Postive Solid Tumor

Start date: December 2019
Phase: Phase 2
Study type: Interventional

This is an open-label, Phase 2 study exploring the efficacy and safety of 马来酸Pyrotinib Maleate Tablets in patients with solid tumors with activating(harmful) HER2 mutations or with HER2 gene amplification or immunohistochemical staining (IHC) assay showing HER2 is 3+ and / or fluorescence in situ hybridization (FISH) positive.